ABSTRACT

Objective: Brain white matter hyperintensities can be divided into periventricular hyperintensity (PVH) and deep-and-subcortical white matter hyperintensity (DSWMH); the former contributes more to cognitive dysfunction and infarction risk. We conducted the present investigation to define the relationship between PVH and DSWMH.

Design: Cross-sectional study.

Setting: University hospital.

Participants: We prospectively enrolled 228 healthy Japanese volunteers with relative risk values (RRVs) >0.5.

Primary outcome measures: We investigated whether it is possible to use the RRV to predict PVH and DSWMH.

Results: Among 228 volunteers, 103 (45.1%) and 157 (68.8%) exhibited PVH and DSWMH, respectively. Age, body mass index and PVH were significant independent determinants of RRV. A significant OR for PVH was noted in the highest RRV tertile compared with the lowest, after adjusting for potential confounding factors. A significant OR for high predicted PVH risk was found for RRV levels as well.

Conclusions: Elevated RRV levels were significantly associated with increased predicted PVH, suggesting that measuring the plasma protein-conjugated acrolein, interleukin 6 and C reactive protein levels may be useful for identifying Japanese at high risk for PVH.

INTRODUCTION

A number of large-scale clinical studies have demonstrated that white matter hyperintensities (WMHs) are associated with high stroke risk.1-3 The results of the large-scale, multicentre open trial PICA study4 conducted in Japan suggest that the Fazekas-classified periventricular hyperintensities (PVHs) and deep-and-subcortical white matter hyperintensities (DSWMHs)5 are related to the risk of symptomatic brain infarction. In the Rotterdam Scan study on elderly patients with no history of stroke, conducted by MRI for 4.2 years, the proportional HR of stroke occurrence after adjustment of comorbid factors was 4.7 (95% CI 2.0 to 11.2) in PVH and 3.6 (CI 1.4 to 9.2) in DSWMH.6 Unlike DSWMH, PVH is associated with cognitive dysfunction.7 In other studies, associations were separately assessed for PVH and DSWMH and was significant only for PVH, which was related to decreased processing speed and executive function.8 9 Additionally, PVH predicted poorer functional outcome after stroke both in the acute and chronic phases, independently of DSWMH.10 11 A Chiba University group reported that the relative risk value (RRV) measured based on protein-conjugated acrolein (PCAcro) together with interleukin 6 (IL-6) and C reactive protein (CRP) can be used to predict the stroke risk factors of silent brain infarction, carotid atherosclerosis, and WMH with high sensitivity and specificity.12 We measured plasma PCAcro, IL-6 and CRP, and analysed the measurements in conjunction with age to determine whether it is possible to use the RRV to predict PVH and DSWMH.
MATERIALS AND METHODS

Subjects and blood sampling
We examined 228 adult volunteers (78 women and 150 men, aged 65.0±7.0 years, range 31–83 years). All these volunteers were healthy, living independently at home without apparent history of stroke, cardiovascular disease or malignancy. Volunteers with RRV >0.5 were enrolled prospectively. Informed consent was provided by each participant, and our study protocol was approved by the Ethics Committees of Nippon Medical School Hospital. Experiments were carried out in accordance with the Declaration of Helsinki principles. Blood samples were collected into tubes containing 5 U/mL heparin and centrifuged at 1500g for 10 min at 4°C.

PCAcro, IL-6 and CRP measurements
Blood samples were drawn from the antecubital vein after overnight fasting. PCAcro (N-(3-formyl-3,4-dehydro-piperidino)-lysine (FDPlysine) in protein) was determined as previously described13 using an ACR-LYSINE ADDUCT ELISA SYSTEM (NOF Corporation, Tokyo, Japan) and 0.01mL plasma. IL-6 and CRP were quantified using an Endogen Human IL-6 ELISA kit (Pierce Biotechnology, Inc, Rockford, Illinois, USA) and a human CRP ELISA kit (Alpha Diagnostic International, San Antonio, Texas, USA), respectively, according to the manufacturers’ protocols. After the reaction was terminated, absorbance was measured at 450 nm using a microplate reader (MTP-800 APC, Hitachi, Tokyo, Japan). The biochemical markers from each participant were measured by an investigator who was blinded to the MRI results (Amine Pharma Research Institute, Chiba, Japan). RRV was calculated with artificial neural networks by back propagation method using NEUROSIM/L software V.4 (Fujitsu, Tokyo, Japan) and represented as the number of participants (per cent of total). The clinical characteristics for each RRV tertile were compared by analysis of variance (ANOVA) for continuous variables and χ² test for categorical variables. The RRVs between the two groups were compared by Student t tests or by ANOVA followed by multiple comparisons with the Bonferroni correction between the two groups. Correlations between RRV and other variables were evaluated with Pearson’s moment correlation coefficient. Factors with a p value <0.05 as determined by Pearson’s correlation analysis were included in a multiple linear regression analysis to identify independent determinants of the RRV. Logistic regression analysis was performed to obtain the ORs for PVH and DSWMH in the three tertiles. All statistical tests were two-sided, and a p value <0.05 was considered as significant.

Imaging
All 228 participants underwent T1-weighted and T2-weighted MRI and fluid-attenuated inversion recovery (FLAIR) at the Nippon Medical School Hospital, Japan, within 1 month after blood sampling. MRI was performed as described previously.10 PVH and DSWMH were defined as hyperintense areas on T2 and FLAIR images without any abnormality on T115 in patients without neurological signs and/or symptoms. The 228 volunteers were classified into 103 volunteers with PVH (38 women and 65 men, aged 68.2±6.0 years, RRV 0.75 ±0.11) and 157 volunteers with WMH (61 women and 96 men, aged 66.7±5.8 years, RRV 0.71±0.12). In more detail, 76 among all the participants had both PVH and DSWMH, with the other 23 having silent brain infarction. Also, 22 participants had a complication of PVH and silent brain infarction, while in 20 participants there was complication of DSWMH and silent brain infarction.

Statistics
All statistical tests were performed using the JMP9.02 software program (SAS Institute, Cary, North Carolina, USA). Continuous variables except for triglyceride levels were expressed as mean±SD. Triglyceride levels were transformed to the common logarithm for statistical analysis and are expressed as the geometric mean because of their skewed distribution. Categorical data are expressed as the number of participants (per cent of total). The clinical characteristics for each RRV tertile were compared by analysis of variance (ANOVA) for continuous variables and χ² test for categorical variables. The RRVs between the two groups were compared by Student t tests or by ANOVA followed by multiple comparisons with the Bonferroni correction between the two groups. Correlations between RRV and other variables were evaluated with Pearson’s moment correlation coefficient. Factors with a p value <0.05 as determined by Pearson’s correlation analysis were included in a multiple linear regression analysis to identify independent determinants of the RRV. Logistic regression analysis was performed to obtain the ORs for PVH and DSWMH in the three tertiles. All statistical tests were two-sided, and a p value <0.05 was considered as significant.

RESULTS
The study participants were divided into tertiles according to RRV (0.50–0.62, 0.63–0.79 and 0.80–0.90 from the lowest to highest tertile, respectively). The participants’ clinical characteristics are summarised in table 1. The mean RRV of the entire subject population was 0.71 ±0.13 and the mean age was 65±7 years. Age, body mass index (BMI), diastolic blood pressure (BP), HDL cholesterol level, triglyceride level, eGFR and current smoking status were significantly different among the groups.

RRVs were significantly higher in participants with older age, lower eGFR or PVH (table 1). A simple correlation analysis showed that RRV was significantly
correlated with age, systolic BP, eGFR and PVH (table 2). Multiple linear regression analysis indicated that BMI ($\beta=0.0026$, $p=0.044$) and PVH ($\beta=0.0380$, $p<0.0001$) were significant independent determinants of RRV.

The results of logistic regression analysis of the association between PVH and RRV are shown in table 3. Significant, unadjusted ORs for PVH were noted in the third RRV tertile ($5.26 (95\% \text{ CI } 2.66 \text{ to } 10.78)$, $p<0.0001$), compared with the first tertile. After adjusting for model 1 (BMI, systolic BP, triglycerides, eGFR and current smoking status), the ORs in the third RRV tertile remained significant ($4.75 (95\% \text{ CI } 2.33 \text{ to } 10.05)$, $p<0.0001$). After adjusting for model 2, we found that the OR in the third RRV tertile 3 was significant ($5.26 (95\% \text{ CI } 2.65 \text{ to } 10.83)$, $p<0.0001$). A significant relationship was observed between RRV and PVH ($p<0.05$), but no such significance was found between RRV and DSWMH (figure 1).

**DISCUSSION**

The present study demonstrated a significant, positive correlation between RRV and PVH in healthy Japanese volunteers. A number of clinical and epidemiological studies have examined the predictive value of RRV for the presence of WMH. However, those studies assessed WMH prevalence; no studies have shown any significant association of RRV with PVH and DSWMH separately. In this regard, our results raise the possibility that RRV predicts the risk of PVH in the healthy Japanese population. With respect to age, these biochemical markers provide a good index of the presence of tissue damage related to PVH.

Recent studies focused on WMH location have reported that functional impairment within 1–3 months after stroke correlated with PVH but not with DSWMH. PVH WMH, especially PVH, has impacts on early functional recovery after ischaemic stroke regardless of the initial stroke severity and other cardiovascular risk factors. Other groups found a significant association between PVH and decreases in processing speed and executive function, but there was no such relationship with DSWMH. Why PVH and DSWMH have different relationships with stroke outcome remains unclear, but several theories have been put forward. DSWMH predominantly disrupts short association fibres that link adjacent gyri, while PVH affects long association fibres that connect the more distant cortical areas. Thus, lesions in various white matter locations may disconnect from different neural networks that affect neural repair processes after stroke. In addition,
PVHs are related to diminished cerebral vasomotor reactivity and subsequent occurrence of cerebral hypoperfusion,\textsuperscript{22} while DSWMHs are generally associated with microangiopathy.\textsuperscript{23} It is clear that regional hypoperfusion is a good predictor of functional outcome.\textsuperscript{24} These findings shed light on why PVH can predict functional stroke outcome and specific cognitive functions.\textsuperscript{11}

Acrolein induces IL-6 production in astrocytes, macrophages and endothelial cells, while IL-6 induces CRP production in hepatocytes. Then, CRP stimulates IL-6 production and IL-6 decreases acrolein toxicity.\textsuperscript{25} Acrolein was thought to be one of the toxic compounds produced from unsaturated fatty acids by active oxygen species such as superoxide anion radicals, hydrogen peroxide and hydroxyl radicals.\textsuperscript{13} These findings may partially explain the pathophysiological mechanisms underlying the association between PVH and the three biomarkers assessed in the present study. Further investigation will be needed for a better understanding of their inter-relationship.

Our multiple linear regression analysis showed that RRV was independently associated with BMI and PVH. Although obesity is believed to be an independent cardiovascular risk factor,\textsuperscript{26} it is still controversial whether BMI is a significant risk factor for stroke.\textsuperscript{27, 28} BMI was previously reported to be correlated with high RRV,\textsuperscript{29} which may be caused by vascular degeneration and endothelial dysfunction associated with hypertension and metabolic disorders. Patients with metabolic syndrome are generally defined as those who have abdominal obesity and two additional metabolic disorders including hypertension, dyslipidaemia and hyperglycaemia.\textsuperscript{30, 31}

Our study has some potential limitations. Because it was a cross-sectional investigation, we could not determine a causal relationship between increased RRV and PVH risk. In addition, the population included healthy Japanese volunteers only. Therefore, it is unclear whether the results can be extrapolated to other populations of poor health, patients with cardiovascular diseases or other ethnic groups. Despite these potential limitations, our findings support the conclusion that elevated RRV is significantly associated with PVH in healthy Japanese volunteers. These results suggest that RRV measurement may be useful for identifying PVH in the general population. This would allow clinicians to follow patients who may be at risk for stroke and cognitive dysfunction.

### Table 2

<table>
<thead>
<tr>
<th>Item</th>
<th>Simple correlation analysis</th>
<th>Multiple linear regression analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Correlation coefficient (r)</td>
<td>p-Value</td>
</tr>
<tr>
<td>Age</td>
<td>0.60</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Male sex</td>
<td>0.05</td>
<td>0.347</td>
</tr>
<tr>
<td>BMI</td>
<td>0.11</td>
<td>0.075</td>
</tr>
<tr>
<td>Systolic BP</td>
<td>0.14</td>
<td>0.026</td>
</tr>
<tr>
<td>Diastolic BP</td>
<td>0.05</td>
<td>0.382</td>
</tr>
<tr>
<td>Total cholesterol</td>
<td>-0.03</td>
<td>0.618</td>
</tr>
<tr>
<td>LDL cholesterol</td>
<td>-0.02</td>
<td>0.669</td>
</tr>
<tr>
<td>HDL cholesterol</td>
<td>0.02</td>
<td>0.731</td>
</tr>
<tr>
<td>Triglyceride§</td>
<td>-0.10</td>
<td>0.130</td>
</tr>
<tr>
<td>Fasting plasma glucose</td>
<td>0.01</td>
<td>0.841</td>
</tr>
<tr>
<td>eGFR</td>
<td>-0.13</td>
<td>0.041</td>
</tr>
<tr>
<td>Current smoking status (Yes=1)</td>
<td>-0.10</td>
<td>0.115</td>
</tr>
<tr>
<td>PVH (Yes=1)</td>
<td>0.26</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>DSWMH (Yes=1)</td>
<td>0.02</td>
<td>0.689</td>
</tr>
</tbody>
</table>

*Not included in the multiple linear regression analysis to avoid multicollinearity with PVH relative risk value.
†Not included in the multiple linear regression analysis because their p values were ≥0.05 in the simple correlation analysis.
‡n=228.
§Log-transformed value.
BMI, body mass index; BP, blood pressure; DSWMH, deep-and-subcortical white matter hyperintensity; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein.

### Table 3

<table>
<thead>
<tr>
<th>Item</th>
<th>Unadjusted</th>
<th>Adjusted*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OR</td>
<td>95% CI</td>
</tr>
<tr>
<td>Tertile 1</td>
<td>1.00</td>
<td>Reference</td>
</tr>
<tr>
<td>Tertile 2</td>
<td>3.13</td>
<td>1.57 to 6.41</td>
</tr>
<tr>
<td>Tertile 3</td>
<td>5.26</td>
<td>2.66 to 10.78</td>
</tr>
</tbody>
</table>

*Adjusted for systolic BP and eGFR.
BP, blood pressure; eGFR, estimated glomerular filtration rate; PVH, periventricular hyperintensity.
Figure 1  (A) Correlation between the relative risk value (RRV) and the periventricular hyperintensity (PVH). (B) Correlation between the RRV and DSWMH. *Significant at p<0.05.

Acknowledgements  The authors thank Dr Mari Adachi and Dr Sadaji Kura at Katsushika Health Center for assisting with the data analyses.

Contributors  AA was involved in conception and design of the study. YN, MH-A, SO and MU participated in analysis and interpretation. AA wrote the article. YN, MM and YK critically revised the article. YN, MH-A, SO and MU participated in final approval of the article. Statistical analysis was carried out by YN and MM. AA was overall responsible for the study.

Funding  This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests  None

Patient consent  Obtained.

Ethics approval  Obtained.

Provenance and peer review  Not commissioned; externally peer reviewed.

Data sharing statement  No additional data are available.

Open Access  This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

REFERENCES


5
Relative risk values of age, acrolein, IL-6 and CRP as markers of periventricular hyperintensities: a cross-sectional study

Arata Abe, Yasuhiro Nishiyama, Mina Harada-Abe, Seiji Okubo, Masayuki Ueda, Masahiro Mishina and Yasuo Katayama

BMJ Open 2014 4:
doi: 10.1136/bmjopen-2014-005598

Updated information and services can be found at:
http://bmjopen.bmj.com/content/4/8/e005598

These include:

References
This article cites 30 articles, 15 of which you can access for free at:
http://bmjopen.bmj.com/content/4/8/e005598#BIBL

Open Access
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Diagnostics (208)
Neurology (391)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/